4,743,328 results match your criteria: "PA; and Pfizer Vaccine Clinical Research and Development[Affiliation]"
Nat Commun
January 2025
Robson DNA Science Centre, Charbonneau Cancer Institute, Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
To tolerate oxidative stress, cells enable DNA repair responses often sensitive to poly(ADP-ribose) (PAR) polymerase 1 and 2 (PARP1/2) inhibition-an intervention effective against cancers lacking BRCA1/2. Here, we demonstrate that mutating the CHD6 chromatin remodeler sensitizes cells to PARP1/2 inhibitors in a manner distinct from BRCA1, and that CHD6 recruitment to DNA damage requires cooperation between PAR- and DNA-binding domains essential for nucleosome sliding activity. CHD6 displays direct PAR-binding, interacts with PARP-1 and other PAR-associated proteins, and combined DNA- and PAR-binding loss eliminates CHD6 relocalization to DNA damage.
View Article and Find Full Text PDFCell Death Discov
January 2025
Department of Gastroenterology, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, 518172, China.
Intestinal fibrosis, as a late-stage complication of inflammatory bowel disease (IBD), leads to bowel obstruction and requires surgical intervention, significantly lowering the quality of life of affected patients. SAA3, a highly conserved member of the serum amyloid A (SAA) apolipoprotein family in mice, is synthesized primarily as an acute phase reactant in response to infection, inflammation and trauma. An increasing number of evidence suggests that SAA3 exerts a vital role in the fibrotic process, even though the underlying mechanisms are not yet fully comprehended.
View Article and Find Full Text PDFTransl Psychiatry
January 2025
Department of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of General Hospital of Northern Theater Command of Jinzhou Medical University, Shenyang, Liaoning, China.
Traumatic brain injury (TBI) is identified as a risk factor for Parkinson's disease (PD), which is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra (SN). However, the precise mechanism by which chronic TBI initiates PD pathogenesis is not yet fully understood. In our present study, we assessed the chronic progression and pathogenesis of PD-like behavior at different intervals in TBI mice.
View Article and Find Full Text PDFCell Death Discov
January 2025
Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
The neuromuscular junction (NMJ) is essential for transmitting signals from motor neurons (MNs) to skeletal muscles (SKMs), and its dysfunction can lead to severe motor disorders. However, our understanding of the NMJ is limited by the absence of accurate human models. Although human induced pluripotent stem cell (iPSC)-derived models have advanced NMJ research, their application is constrained by challenges such as limited differentiation efficiency, lengthy generation times, and cryopreservation difficulties.
View Article and Find Full Text PDFZhonghua Nei Ke Za Zhi
February 2025
Department of Rheumatology and Immunology, the First Medical Center of Chinese PLA General Hospital, Beijing100853, China.
Zhonghua Nei Ke Za Zhi
February 2025
Department of Endocrinology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou450003, China.
Zhonghua Nei Ke Za Zhi
February 2025
Department of Ultrasound Medicine, China-Japan Friendship Hospital, Beijing100029, China Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing100730, China National Respiratory Medicine Center, National Key Laboratory of Respiratory and Comorbidity, National Respiratory Medical Center National Clinical Research Center, Respiratory Diseases Respiratory Research Institute of Chinese Academy of Medical Sciences, Respiratory Center of China-Japan Friendship Hospital, Beijing100029, China.
Zhonghua Fu Chan Ke Za Zhi
January 2025
Zhonghua Fu Chan Ke Za Zhi
January 2025
Zhonghua Fu Chan Ke Za Zhi
January 2025
Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing100021, China.
To analyze the clinical characteristics, treatments, and prognosis of patients with ovarian juvenile granulosa cell tumor (JGCT). Clinical and pathological data, and follow-up information of 34 patients diagnosed with JGCT from 2000 to 2021 were collected from the surveillance, epidemiology, and end results (SEER) database. A retrospective analysis was conducted to summarize the patients' clinical and pathological characteristics, treatments, and prognosis.
View Article and Find Full Text PDFZhonghua Fu Chan Ke Za Zhi
January 2025
Gynecological Minimally Invasive Center, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100006, China.
To investigate the correlation between uterine volume and intrauterine adhesion (IUA). From June 2018 to November 2019, totally 7 007 patients who underwent hysteroscopy in outpatient operating rooms of Gynecological Minimally Invasive Center, Beijing Obstetrics and Gynecology Hospital were retrospectively analyzed Patients of reproductive age with IUA without uterine fibroids and adenomyosis were selected as IUA group, and patients of reproductive age without uterine fibroids and adenomyosis without IUA during the same period were selected as the control group. The propensity score matching (PSM) method was used to perform 1∶1 matching for the two groups of patients, matching variables included age, height, weight, body mass index (BMI), gravidity, parity, and number of abortion curettage.
View Article and Find Full Text PDFZhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing 210029, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, Peking University Health Science Center, Beijing 100191, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, U S A.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, the First People's Hospital of Changzhou, Jiangsu Province, Changzhou 213000, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, the First People's Hospital of Lianyungang, Affiliated Hospital of Xuzhou Medical university, Lianyungang 222000, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Departmen of Pathology, Jiangsu Province (Suqian) Hospital/Suqian First Hospital, Suqian 223800, China.